PLATO研究与临床意义.pptVIP

Title: PLATO研究 Key Points: PLATO研究 tested the hypothesis that… 替格瑞洛 will result in a lower risk of recurrent thrombotic events in a broad patient population with ACS as compared to 氯吡格雷 and this would be achieved with a clinically acceptable bleeding rate and overall safety profile PLATO研究: 43 countries 862 sites 18,624 patients Additional Information: N/A Reference: Wallentin L, Becker RC, Bujah A, et al. 替格瑞洛 versus 氯吡格雷 in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057. * PLEASE NOTE THAT USE OF THESE MATERIALS IS SUBJECT TO LOCAL APPROVAL AND MUST BE “SIGNED OFF” BY YOUR LOCAL 否心梗NATED SIGNATORY These slides are dated July 2010 with information known to AstraZeneca Medical Affairs at that time; they will be amended when new information and/or label approvals occur Title: PLATO研究: Study Population Key Points: PLATO研究 was designed to reflect current clinical practice PLATO研究 rando心梗zed A broad spectrum of patients with ACS, based on initial presentation, and ECG within 24 hours 不稳定性心绞痛, NSTEMI or STEMI Both invasive or non-invasively managed patients at the time treatment was planned, regardless of whether or not it was performed Among STEMI patients, only those intended for primary PCI were included In PLATO研究, patients rando心梗sed prior to angiography and elucidation of coronary anatomy Additional Information: For patients who had ACS without ST-segment elevation, at least 2 of the following 3 criteria had to be met: ST-segment changes on ECG, indicating ischae心梗a; a positive test of a biomarker, indicating myocardial necrosis; or one of several risk factors (age ≥60 years; previous 心梗 or CABG; coronary artery disease with stenosis of ≥50% in at least 2 vessels; previous ischae心梗c 卒中, TIA, carotid stenosis of at least 50%, or cerebral revascularisation; DM; PAD; or chronic renal dysfunction, defined as a creatinine clearance of 60 mL per 心梗nute per 1.73 m2 of body surface area) For patients who had ACS with ST-segment elev